Unveiling 6 Analyst Insights On United Therapeutics

United Therapeutics (NASDAQ:UTHR) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below offers a condensed view of their rece

Benzinga02:01

United Therapeutics Is Maintained at Buy by UBS

United Therapeutics Is Maintained at Buy by UBS

Dow Jones00:05

UBS Maintains Buy on United Therapeutics, Raises Price Target to $370

UBS analyst Ashwani Verma maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $300 to $370.

BenzingaJul 8 23:55

United Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 16.91% UBS $300 → $370 Maintains Buy 06/12/2024 10.6% Wells Fargo $325 → $350 Maintains Overwei

BenzingaJul 8 23:51

UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating

United Therapeutics (UTHR) has an average outperform rating and a price target range of $221 to $400, according to analysts polled by Capital IQ.

MT NewswiresJul 8 21:23

Express News | United Therapeutics Corp : UBS Raises Target Price to $370 From $300

BreakingsJul 8 20:31